FDA files an interim plan to let pharmacies compound certain peptides

What happened

On October 14, 2026, the White House Office of Information and Regulatory Affairs (OIRA) received an FDA notice titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94). The public listing shows it as a notice under review. It carries no summary yet, so the list of peptides it covers is not public.

OIRA review is the step a policy like this passes through before it is published. Nothing in the listing says when that will be.

Why it matters

In April 2026, FDA said it would take 12 peptides off its Category 2 list of bulk substances that raise safety concerns, among them BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and injectable GHK-Cu. Coming off that list did not by itself let pharmacies compound them: FDA's current interim policy covers Category 1 substances only, so those peptides have sat in between.

An interim access policy is the kind of bridge that could let some of them be compounded while the formal rules are written. On October 7 the Washington Post reported that the administration was preparing a plan that would allow some compounding pharmacies to dispense certain peptides. This filing is the first formal paperwork for it.

What it means for you

Until the policy is published, nothing changes: the peptides on that April list still can't be compounded, and research-grade vials are what most people run. If the policy covers them, a prescription from a compounding pharmacy could become a route for some of them, with the pharmacy standards that come with it.

The detail to watch for is the list itself: which peptides, which routes (GHK-Cu was cleared for injection only), and what a pharmacy must do to dispense them.

What's next

OIRA reviews can take days or months. When FDA publishes the notice, its text will name the peptides and the conditions. FDA's own drug staff have reportedly questioned the plan, so its final scope may be narrower than the hope around it.